Core Viewpoint - Novo Nordisk (NVO.US) is suing Hims & Hers (HIMS.US) for allegedly producing counterfeit versions of its weight loss drug, Wegovy, and has accused Hims of patent infringement regarding the active ingredient semaglutide [1][2]. Group 1: Legal Actions and Allegations - Novo Nordisk claims that Hims has infringed its semaglutide patent in the U.S., which is the active ingredient in its blockbuster drugs Ozempic and Wegovy [1]. - The lawsuit was filed in Delaware, with Novo Nordisk seeking damages including "reasonable royalties" and lost profits due to Hims' actions [2]. - Hims had previously announced a compound weight loss drug, prompting strong reactions from Novo Nordisk and regulatory bodies, leading Hims to abandon its plans to sell the counterfeit version [1][2]. Group 2: Company Responses and Market Impact - Novo Nordisk's legal counsel expressed outrage over Hims' decision to launch a counterfeit product, marking a significant turning point in their relationship [1]. - Following the announcement of the lawsuit, Hims' stock price fell by 21%, while Novo Nordisk's shares rose nearly 6% [3]. - The FDA has committed to taking action against counterfeit weight loss drugs, and Hims has been referred to the Department of Justice for potential federal law violations [3].

"我们很高兴找到方法，继续通过平台跨专科推出品牌治疗方案。对客户而言，平台上有更多选择是最 好的事情，"Hims首席执行官Andrew Dudum在一份声明中说。 周四，Hims&Hers Health(HIMS.US)盘前大涨近14%，报27.77美元。消息面上，据报道，该公司以每月 49美元的优惠价开始提供新推出的Wegovy药片的仿制版，较品牌药物便宜约100美元。Hims表示，该疗 法可以针对希望避免副作用或更喜欢药片而非注射选项的患者进行定制。 ...

Group 1 - The CEO of GPCR, Raymond Stevens, expressed concerns about the influx of generic versions of their experimental weight loss drug, which has not yet been approved [1] - Following the launch of weight loss injections by Eli Lilly and Novo Nordisk, patients turned to generics due to supply shortages, although these shortages have since ended [1] - The CEO of Novo Nordisk indicated that up to 1.5 million patients in the U.S. are using compounded weight loss drugs, highlighting the ongoing issue of generics in the market [1] Group 2 - Pharmaceutical companies claim that the FDA has not done enough to prevent the spread of generics, with a recent statement indicating plans to publish a list of overseas suppliers that meet FDA standards [2] - Compounding pharmacies utilize these raw materials to produce their own branded generic versions of drugs like Wegovy and Zepbound [2] Group 3 - Stevens noted that GPCR's aleniglipron is a small molecule drug with a more complex manufacturing process, making it harder to replicate compared to peptide drugs like Zepbound and Wegovy from Eli Lilly and Novo Nordisk [1]